This is a phase 1, "first in man" study to evaluate single oral doses (5-300 mg) of SQ109, a
new investigational drug being developed for treatment of tuberculosis. If single doses are
safe and well tolerated, subsequent studies will evaluate multiple daily doses in healthy
volunteers and patients with pulmonary tuberculosis.